Radiographic pattern of progression of recurrent GBM treated with bevacizumab with or without irinotecan.

被引：0
|
作者：
Dory-Lautrec, P. [1 ]
Tabouret, E. [1 ]
Barrie, M. [1 ]
Boucard, C. [1 ]
Matta, M. [1 ]
Autran, D. [1 ]
Girard, N. [1 ]
Chinot, O. L. [1 ]
机构：
[1] Univ Hosp Timone, Marseille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.2091
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2091
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Radiographic evaluation of recurrent glioblastoma multiforme (GBM) in patients treated with bevacizumab and irinotecan
    Andre, J.
    Spearman, K.
    Lu, S.
    Hwang, S.
    Dorsett, L.
    Raval, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Radiographic evaluation of recurrent glioblastoma multiforme (gbm) in patients treated with bevacizumab and irinotecan
    Andre, Jalal
    Spearman, Kenneth
    Lu, Stanley
    Raval, Sumul
    NEURO-ONCOLOGY, 2007, 9 (04) : 575 - 575
  • [3] Circulating endothelial cells and progenitors in recurrent high-grade gliomas treated with bevacizumab and irinotecan.
    Eoli, M.
    Calleri, A.
    Cuppini, L.
    Anghileri, E.
    Pellegatta, S.
    Prodi, E.
    Bruzzone, M. G.
    Bertolini, F.
    Finocchiaro, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Bevacizumab and irinotecan in patients with recurrent glioblastoma multiforme (GBM)
    Raval, Sumul N.
    Rule, Amy
    Hwang, Shirley S.
    NEURO-ONCOLOGY, 2006, 8 (04) : 482 - 482
  • [5] Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM)
    Raval, S.
    Hwang, S.
    Dorsett, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM)
    Gilbert, M. R.
    Wang, M.
    Aldape, K.
    Lassman, A.
    Sorensen, A. G.
    Mikkelson, T.
    Groves, M.
    Werner-Wasik, M.
    Regine, W.
    Mehta, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Bevacizumab/Irinotecan. An active treatment for recurrent high grade gliomas: Preliminary results of an ANOCEF Multicenter Study
    Guiu, S.
    Taillibert, S.
    Chinot, O.
    Taillandier, L.
    Honnorat, J.
    Dietrich, P. Y.
    Maire, J. -P.
    Guillamo, J. S.
    Guiu, B.
    Catry-Thomas, I.
    Capelle, F.
    Thiebaut, A.
    Cartalat-Carel, S.
    Deville, C.
    Fumoleau, P.
    Desjardins, A.
    Xuan, K. Hoang
    Chauffert, B.
    REVUE NEUROLOGIQUE, 2008, 164 (6-7) : 588 - 594
  • [8] SALVAGE CONCURRENT CHEMOTHERAPY WITH BEVACIZUMAB FOR RECURRENT MALIGNANT GLIOMAS PREVIOUSLY TREATED WITH BEVACIZUMAB AND IRINOTECAN
    Torcuator, Roy
    Zuniga, Richard
    Doyle, Thomas
    Anderson, Joseph
    Mikkelsen, Tom
    NEURO-ONCOLOGY, 2008, 10 (05) : 829 - 829
  • [9] CLINICAL PREDICTIVE FACTORS OF INCREASE OVERALL SURVIVAL WITH BEVACIZUMAB/IRINOTECAN FOR PRIMARY RECURRENT GLIOBLASTOMA (GBM)
    Frenel, J. S.
    Leux, C.
    Tollec, S.
    Martin, S.
    Labbe, C.
    Loussouarn, D.
    Campone, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 330 - 330
  • [10] Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
    Reardon, David A.
    Desjardins, Annick
    Peters, Katherine B.
    Vredenburgh, James J.
    Gururangan, Sridharan
    Sampson, John H.
    McLendon, Roger E.
    Herndon, James E., II
    Coan, April
    Threatt, Stevie
    Friedman, Allan H.
    Friedman, Henry S.
    CANCER, 2011, 117 (23) : 5351 - 5358
12345